David Shaw’s Phathom Pharmaceuticals PHAT Stock Holding History

David Shaw’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Sell	95,660 -36,797	-28%	-$420K	﹤0.01%	3717
2026 Q1	$1.47M	Sell	132,457 -128,611	-49%	-$1.62M	﹤0.01%	3153
2025 Q4	$4.33M	Buy	+261,068	New	+$3.73M	﹤0.01%	2430
2024 Q4	–	Sell	-143,707	Closed	-$2.6M	–	4752
2024 Q3	$2.6M	Buy	+143,707	New	+$2.01M	﹤0.01%	2493
2024 Q2	–	Sell	-64,138	Closed	-$681K	–	4771
2024 Q1	$681K	Sell	64,138 -65,251	-50%	-$554K	﹤0.01%	3322
2023 Q4	$1.18M	Sell	129,389 -1,175	-0.9%	-$10.1K	﹤0.01%	3028
2023 Q3	$1.35M	Buy	130,564 +16,871	+15%	+$231K	﹤0.01%	2874
2023 Q2	$1.63M	Buy	+113,693	New	+$1.31M	﹤0.01%	2766
2022 Q4	–	Sell	-14,477	Closed	-$160K	–	5055
2022 Q3	$160K	Sell	14,477 -47,781	-77%	-$455K	﹤0.01%	4526
2022 Q2	$525K	Buy	+62,258	New	+$640K	﹤0.01%	4061
2020 Q1	–	Sell	-7,528	Closed	-$234K	–	4174
2019 Q4	$234K	Buy	+7,528	New	+$189K	﹤0.01%	3734

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

GKIM

GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

David Shaw's PHAT Position: Q2 2026 in Review

David Shaw reduced its Phathom Pharmaceuticals (PHAT) stake by 28% in Q2 2026, selling an estimated $420K and leaving 95,660 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #3717.

David Shaw first reported a position in PHAT in Q4 2019 and has held it in 11 quarters since. The position peaked at $4.33M in Q4 2025. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

David Shaw held 95,660 shares of Phathom Pharmaceuticals worth $1.04M as of Q2 2026.
David Shaw sold 36,797 Phathom Pharmaceuticals shares in Q2 2026, an estimated $420K.
Phathom Pharmaceuticals made up ﹤0.01% of David Shaw's portfolio in Q2 2026, its #3717 holding.
David Shaw first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 11 quarters since.
David Shaw's Phathom Pharmaceuticals position peaked at $4.33M in Q4 2025.
161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.